StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

Stock analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Thursday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.06.

OncoCyte Stock Up 2.0 %

OCX opened at $3.05 on Thursday. The company has a fifty day moving average of $3.09 and a 200 day moving average of $2.93. OncoCyte has a fifty-two week low of $2.08 and a fifty-two week high of $4.34.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The firm had revenue of $0.10 million for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.